BI
BVF Inc Portfolio holdings
AUM
$2.8B
This Quarter Return
+22.52%
1 Year Return
+17.96%
3 Year Return
+404.14%
5 Year Return
+563.41%
10 Year Return
+5,885.83%
AUM
$986M
AUM Growth
+$986M
(+19%)
Cap. Flow
+$53.1M
Cap. Flow
% of AUM
5.38%
Top 10 Holdings %
Top 10 Hldgs %
59.81%
Holding
51
New
8
Increased
8
Reduced
13
Closed
7
Top Buys
| 1 |
Ironwood Pharmaceuticals
IRWD
|
$85.5M |
| 2 |
Merus
MRUS
|
$44.8M |
| 3 |
Xencor
XNCR
|
$27M |
| 4 |
Arcus Biosciences
RCUS
|
$19.6M |
| 5 |
Corvus Pharmaceuticals
CRVS
|
$17.2M |
Top Sells
| 1 |
ARRY
Array Biopharma Inc
ARRY
|
$59.1M |
| 2 |
CytomX Therapeutics
CTMX
|
$23.7M |
| 3 |
AnaptysBio
ANAB
|
$21.7M |
| 4 |
Xenon Pharmaceuticals
XENE
|
$14.1M |
| 5 |
CASC
Cascadian Therapeutics, Inc.
CASC
|
$11.6M |
Sector Composition
| 1 | Healthcare | 83.17% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
CCXI
1
DELISTED
ChemoCentryx, Inc.
CCXI
| $97.9M | 9.93% | 7,201,316 -386,100 | -5% | -$5.25M |
|
|
2
Ironwood Pharmaceuticals
IRWD
$214M
| $85.5M | 8.67% | +5,542,400 | New | +$85.5M |
|
|
ARRY
3
DELISTED
Array Biopharma Inc
ARRY
| $82.6M | 8.38% | 5,062,768 -3,623,730 | -42% | -$59.1M |
|
|
BPMC
4
DELISTED
Blueprint Medicines
BPMC
| $60.1M | 6.09% | 655,611 -111,743 | -15% | -$10.2M |
|
|
ARQL
5
DELISTED
Arqule Inc
ARQL
| $47.3M | 4.8% | 16,436,912 | – | – |
|
6
Syndax Pharmaceuticals
SNDX
$1.41B
| $46M | 4.66% | 3,233,618 | – | – |
|
|
7
Merus
MRUS
$4.98B
| $44.8M | 4.54% | +2,419,443 | New | +$44.8M |
|
|
CNCE
8
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
| $44.2M | 4.49% | 1,932,123 -37,666 | -2% | -$863K |
|
9
Cytokinetics
CYTK
$4.23B
| $41.2M | 4.18% | 5,721,888 | – | – |
|
|
10
AnaptysBio
ANAB
$569M
| $40.2M | 4.07% | 386,065 -208,332 | -35% | -$21.7M |
|
11
Xoma
XOMA
$392M
| $30.4M | 3.08% | 1,502,800 | – | – |
|
|
12
Xencor
XNCR
$580M
| $27M | 2.74% | +902,000 | New | +$27M |
|
|
CTIC
13
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
| $27M | 2.74% | 6,929,690 -1,666,667 | -19% | -$6.5M |
|
14
Kura Oncology
KURA
$686M
| $25.4M | 2.57% | 1,353,846 | – | – |
|
|
PVLA
15
Palvella Therapeutics, Inc. Common Stock
PVLA
$599M
| $24.5M | 2.48% | 3,592,549 +968,987 | +37% | +$6.61M |
|
|
BLRX
16
BioLineRX
BLRX
$16.2M
| $22.6M | 2.29% | 25,995,575 | – | – |
|
|
17
Corvus Pharmaceuticals
CRVS
$428M
| $22.5M | 2.28% | 1,954,254 +1,494,858 | +325% | +$17.2M |
|
|
INFI
18
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
| $20.5M | 2.08% | 9,766,508 | – | – |
|
|
19
Arcus Biosciences
RCUS
$1.13B
| $19.6M | 1.99% | +1,269,788 | New | +$19.6M |
|
20
Spero Therapeutics
SPRO
$116M
| $14.9M | 1.52% | 1,048,958 +19,773 | +2% | +$282K |
|
|
IMDZ
21
DELISTED
Immune Design Corp.
IMDZ
| $13.6M | 1.37% | 4,106,200 +2,636,400 | +179% | +$8.7M |
|
|
OMED
22
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
| $13.5M | 1.37% | 4,253,189 -18,100 | -0.4% | -$57.6K |
|
|
PHXM
23
DELISTED
PHAXIAM Therapeutics S.A.. American Depositary Shares
PHXM
| $13.1M | 1.33% | 625,000 | – | – |
|
|
FSTX
24
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
| $12.8M | 1.3% | 832,247 +8,773 | +1% | +$135K |
|
|
VBIV
25
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
| $10.9M | 1.1% | 3,100,000 | – | – |
|